Abstract
Serum concentrations of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) were measured in 51 liver cirrhosis, 37 chronic active hepatitis (CAH) patients and 26 healthy individuals. Elevated PSA levels have been found in 2 of cirrhotic patients while no increase has been detected in CAH and controls. Serum PAP levels have been observed slightly increased in 2 patients with cirrhosis, 2 patients with CAH and 1 control case. Mean PSA and mean PAP values showed no significant difference between groups (p>0.05). Serum PSA and PAP levels are reliable in diagnosing and monitoring prostate cancer in chronic liver patients and maintain their specificity in this situation.
Similar content being viewed by others
References
Schwartz, M. K.: Cancer markers. In: Cancer, Principles and Practice of Oncology. J. B. Lippincott, Philadelphia 1993.
Akdas, A., Şimşek, F., Ilker, Y., Türkeri, L., Ercan, H.: The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.Int. Urol. Nephrol., 25, 271 (1993).
Minton, J. P., Chewinsky, A.: Present status of serum markers.Sem. Surg. Oncol., 5, 426 (1989).
Jacops, E. L., Haskell, C. M.: Clinical use of tumor markers in oncology.Curr. Prob. Cancer, 6, 301 (1991).
Kadayifci, A., Ozyilkan, E., Şimşek, H., Sivri, B., Kayhan, B., Ozkuyumcu, C., Telatar, H.: The elevation of serum tumor markers CA 19-9 and CA 125 in chronic liver disease type B and C.Eur. J. Cancer, 29A (Suppl. 6), 245 (1993)
Henneberry, M. D., Engel, G., Grayhack, J. T.: Acid phosphatase.Urol. Clin. North Am., 6, 629 (1979).
DiPaolo, C. J., Rival, J.: Acid phosphatase: Clinical utility of the first tumor marker.Henry Ford Hosp. Med. J., 30, 70 (1982).
Heller, J. E.: Prostatic acid phosphatase: Its current clinical status.J. Urol., 137, 1091 (1987).
Tavassoli, M., Rizo, M., Yam, L. T.: Elevation of serum acid phosphatase in cancers with bone metastasis.Cancer, 45, 2400 (1980).
Cooper, J. F.: The radioimmunochemical measurement of prostatic acid phosphatase: Current state of the art.Urol. Clin. North. Am., 7, 653 (1980).
Ruckle, H. C., Klee, G. G., Oesterling, J. E.: Prostate specific antigen: Critical issues for practising physicians.Mayo Clin. Proc., 69, 59 (1994).
Ashwell, G., Morell, A. G.: The role of surface carbohydrates in the hepatic recognition and transport of circulating glicoproteins.Adv. Enz. Relat. Areas Mol. Biol. 41, 99 (1974).
Putzki, H., Ledwoch, J.: Tumor markers CEA, TPA, and CA 19-9 in liver diseases.J. Surg. Oncol., 37, 133 (1987).
Virji, M. A., Mercer, D. W., Herberman, R.: New immunologic markers for monitoring of cancer.Ann. Chir. Gynaecol., 78, 13 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kadayifci, A., Benekli, M., Şimşek, H. et al. Prostatic acid phosphatase and prostate specific antigen in liver disease. International Urology and Nephrology 28, 67–71 (1996). https://doi.org/10.1007/BF02550140
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02550140